Another consensus document proposed no discontinuation of prophylaxis until peripheral blood CD4+ T-cell count recovers to more than 200 cells/mL, as alemtuzumab-associated lymphopenia clinically behaves like that seen in patients with HIV infection [27]. The gene discussed is CD4; the disease is lymphopenia.